Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

udy enrolled prior to the fourth quarter of 2013.
  • Phase III study of ibrutinib versus chlorambucil in frontline newly diagnosed elderly CLL/SLL patients, RESONATE™ -2.  This trial is a randomized, multicenter, open-label study of ibrutinib as a monotherapy versus chlorambucil in patients 65 years or older with treatment naïve CLL/SLL. The study design was granted a Special Protocol Assessment (SPA), designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival when compared to chlorambucil. This global study is open and Pharmacyclics plans to enroll 272 patients worldwide. The Company anticipates enrollment for this study will take approximately 18 months to complete. 
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL, HELIOS (CLL3001). This trial is a randomized, multi-center, double blinded, placebo controlled trial of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™ -17p, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment with chemo immunotherapy (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company anticipates enrollment for this study will take approximately 12 months to complete.
  • Phase III study of ibrutinib ver
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/31/2015)... Campbell, California (PRWEB) March 31, 2015 ... management consulting firm with operations in California, Oregon, ... formal launch of its Merger and Acquisition (M&A) ... , Peter Adams, VP Client Services and M&A ... repeatedly shown that the vast majority of M&A ...
    (Date:3/30/2015)... 2015 PMG Research, Benchmark Research, ... the formation of VaxCorps, a network of highly ... the conduct of vaccine trials in healthy adult, ... have successfully conducted over 500 phase I-III vaccine ... pandemic influenza as well as a vast array ...
    (Date:3/30/2015)... -- Heidrick & Struggles (Nasdaq: HSII ), the premier provider ... culture shaping worldwide, today  announced that John ... Healthcare and Life Sciences practice. As Global Practice ... a team of more than 80 partners, principals and associates ... Asia serving clients in the biopharmaceutical, medical ...
    (Date:3/30/2015)... NEW BRUNSWICK, N.J. , March 30, 2015 /PRNewswire-USNewswire/ ... research and innovation projects in the state of ... to its next round of grant funding, announced ... existing New Jersey Health Foundation Research Grants program, an ... to $35,000 each to fund early stage research projects ...
    Breaking Biology Technology:Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2
    ... Them Waiting, WASHINGTON, April 16 With dozens ... to meet with members of,Congress, The Coalition for a ... members to keep the best interests of,patients in mind ... for safe, effective and affordable biogeneric medicines., The ...
    ... N.Y., April 16 Biotech and pharma,companies are ... work, reports Genetic Engineering & Biotechnology News (GEN). ... means of testing drug,candidates for toxic effects, according ... GEN ( http://www.genengnews.com/articles/chitem.aspx?aid=2437 )., "Better screening technologies, ...
    ... 16 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" or the ... restructuring efforts., The Board of Directors of Chromos ... President and Chief Executive Officer, effective,immediately. He has also ... of the Company, served as President and CEO since ...
    Cached Biology Technology:Diverse Coalition of Purchasers Respond to BIO CEO Fly-In: There is Another Side to The Story 2Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays 2Chromos provides shareholder update 2
    (Date:3/18/2015)... CORAL SPRINGS, Florida , March 18, 2015 ... as well as businesses, new revolutionary smart wallets and apps ... rapid pace.  Companies currently entrenched in the mobile payment industry ... ), Alibaba Group Holding Ltd. (NYSE: BABA ), ... GOOG ) and Facebook Inc. (NASDAQ: ...
    (Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
    (Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
    Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
    ... been developed that allows water to be used twice ... system. , The Green Roof Water Recycling System (GROW) ... can then be reused for activities such as flushing ... Chris Shirley-Smith, whose company Water Works UK is collaborating ...
    ... collaboration effort in Mongolia to be used in development ... from wild birds in Mongolia by field veterinarians from ... been selected by the World Health Organization to be ... in development. The samples, collected in the ...
    ... and biology now have access to one of the most ... Spectral Imaging Facility, opened this fall, is a combination of ... the first commercial machine of its kind. , The atomic ... and the confocal microscope system by Olympus America Inc. Integration ...
    Cached Biology News:GROWing the next generation of water recycling plants 2Wild birds help to create human flu vaccine 2Wild birds help to create human flu vaccine 3
    Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
    ... HT, 1 kit. Facilitates the simple, phenol-free ... and hard tissue requiring proteinase K digestion.Each ... DNA from 50 preparations of up to ... Synthesis & Purification, Purification and Amplification of ...
    Request Info...
    Ultra-sensitive, non-radioactive measurement of COX-I and COX-II activity...
    Biology Products: